TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Golconda Gold Ltd. (“Golconda Gold” or the “Company”) (TSX-V: GG; OTCQB: GGGOF) is pleased to announce that it has been included in the TSX Venture 50 list. TSX Venture 50 is a ranking of the 50 top-performing companies on the TSX Venture Exchange over the last year. Companies are ranked based on three equally-weighted criteria of one-year share price appreciation, market capitalization increase, and Canadian consolidated trading value. Ravi Sood, Chief Executive O ...

HOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) (“Vaalco” or the “Company”) announced that it will be participating in SpareBank 1 Markets Energy Conference to be held in Oslo, Norway where Chief Executive Officer George Maxwell is scheduled to make a presentation on Wednesday, February 25, 2026. In conjunction with this press release, the Company has posted an updated investor presentation to its website. The presentation is available at the following link: (https://www ...

Core Viewpoint - Phillips Edison & Company, Inc. (PECO) has announced a public offering of $350 million in senior unsecured notes with a 4.750% interest rate, maturing in 2033, to support various corporate purposes [1][2]. Group 1: Offering Details - The public offering is priced at 99.920% of the principal amount and is expected to settle on February 26, 2026, pending customary closing conditions [1]. - The notes will be fully and unconditionally guaranteed by PECO [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including repaying borrowings under the revolving credit facility, term loans, acquiring additional properties, capital expenditures, and working capital [2]. Group 3: Underwriters - The offering is managed by a consortium of financial institutions including Wells Fargo Securities, BMO Capital Markets, and BofA Securities, among others [3]. Group 4: Company Overview - PECO is one of the largest owners and operators of grocery-anchored neighborhood shopping centers in the U.S., managing 324 shopping centers as of December 31, 2025, with a total of 33.5 million square feet across 31 states [6]. - The company focuses on creating grocery-anchored shopping experiences and improving communities [6].

Net Income per Diluted Share of $0.99 for the Fourth Quarter and $10.84 for the Full Year of 2025 Core FFO per Share of $1.40 for the Fourth Quarter and $6.68 for the Full Year of 2025 North America Same Property NOI increased by 7.9% for the Fourth Quarter and 5.7% for the Full Year of 2025 Acquired 14 MH and RV Communities for $457.0 million and Distributed Over $1.5 Billion of Capital to Shareholders, Inclusive of Cash Distributions and Share Repurchases in 2025 Establishing Guid ...

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the 46th Annual TD Cowen Healthcare Conference, taking place March 2-4, 2026 in Boston, MA. 46th A ...

SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (NASDAQ: ANTA) ("Antalpha" or the "Company"), a leading institutional digital asset financing platform, today announced that it will report its financial results for the fourth quarter and full year 2025 before the U.S. market open on March 3, 2026. The Company’s management team will hold a conference call at 8:00 A.M. U.S. Eastern Time on March 3, 2026 (or 9:00 P.M. Singapore Time on March 3, 2026) to discuss the financial resul ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Inspired Entertainment, Inc. ("Inspired" or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, announced that it will report financial results for the fourth quarter and full year ended December 31, 2025 before the market opens on Tuesday, March 10, 2026. Inspired management will host a conference call and simultaneous webcast the same day at 8:30 a.m. ET / 12:30 p.m. in the UK to discuss the Company's resul ...

Core Insights - Cardiff Oncology reported positive results from the Phase 2 CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer (mCRC), showing a robust objective response rate (ORR) of 72.2% with the 30 mg onvansertib + FOLFIRI/bev combination, compared to 43.2% with standard of care (SoC) [1][5] - The trial also demonstrated a significant improvement in progression-free survival (PFS) with a hazard ratio (HR) of 0.37, indicating a strong potential for onvansertib to enhance patient outcomes [1][5] - The company plans to advance the 30 mg dose of onvansertib into a registrational program, with detailed data and plans expected in the first half of 2026 [1][2] Clinical Development - The CRDF-004 trial results indicate a consistent, dose-dependent treatment benefit, with nearly a 30% improvement in response rate over the control arm and encouraging durability trends in PFS [2][5] - The company has not observed significant added toxicity with the 30 mg onvansertib dose in combination with FOLFIRI/bev, supporting its advancement into registrational development [5] Financial Performance - For the year ended December 31, 2025, Cardiff Oncology reported total operating expenses of approximately $49.6 million, a slight increase from $49.3 million in 2024, primarily due to higher selling, general, and administrative expenses [8][14] - The company reported a net loss of $45.876 million for 2025, compared to a net loss of $45.455 million in 2024, with a net loss per common share of $0.69 [14] - As of December 31, 2025, Cardiff had approximately $58.3 million in cash and cash equivalents, sufficient to fund operations into the first quarter of 2027 [7] Leadership Changes - In January 2026, Cardiff announced executive leadership changes to support its transition into late-stage clinical development, appointing Mani Mohindru as interim Chief Executive Officer [4] - The company is actively searching for a permanent Chief Executive Officer and Chief Financial Officer to strengthen its leadership team [4]

Company Overview - Teva Pharmaceutical Industries Ltd. is transforming into a leading innovative biopharmaceutical company, supported by a world-class generics business [3] - The company has a commitment to improving health for over 120 years, focusing on neuroscience, immunology, complex generic medicines, biosimilars, and pharmacy brands globally [3] Upcoming Events - Richard Francis, Teva's President and CEO, will participate in several investor conferences in March 2026, including the UBS European Healthcare Conference on March 3, the Leerink Partners Global Healthcare Conference on March 9, and the Barclays 28th Annual Global Healthcare Conference on March 10 [1][6] - Live webcasts of the presentations will be available on Teva's Investor Relations website, with archived versions accessible for 30 days after the events [2][1]

Core Insights - UFP Technologies, Inc. reported a net income of $68.3 million for 2025, a 15.8% increase from $59.0 million in 2024, with adjusted net income growing 12.7% to $76.1 million [1][3] - Net sales for 2025 reached $602.8 million, representing a 19.5% increase from $504.4 million in 2024 [1][4] - The company experienced a 23.2% increase in medical sales, while non-medical sales decreased by 11.5% [3][4] Financial Performance - For Q4 2025, sales increased by 3.4% to $148.9 million compared to $144.1 million in Q4 2024 [4] - Year-to-date sales for 2025 increased by 19.5% to $602.8 million from $504.4 million in 2024 [4] - Gross margin for Q4 2025 was 28.2%, down from 29.2% in Q4 2024, while the full-year gross margin decreased to 28.3% from 29.1% [4][5] Operating Income and Expenses - Operating income for the year increased by 14.1% to $92.3 million from $80.9 million in 2024 [9] - Selling, general and administrative expenses (SG&A) rose by 24.5% to $77.4 million for the year, with SG&A as a percentage of sales increasing to 12.8% from 12.3% [5][9] Strategic Initiatives - The company expanded its operations in the Dominican Republic, extending contracts and launching new programs [3] - Four acquisitions in 2024 and three in 2025 are progressing well, with integrations either underway or complete [3] Market Segmentation - Medical market sales for 2025 were $555.3 million, a 23.2% increase, while non-medical sales decreased to $47.5 million [4][9] - Organic sales growth for the year was approximately 1.5%, with Q4 organic sales remaining flat compared to the same period in 2024 [4][18]